Tolerability and Activity of the Chemotherapy-Free Triplet TGR-1202, Ublituximab, and Ibrutinib in Patients with Advanced CLL and NHL

Conference Correspondent - ASCO 2017 - Chronic Lymphocytic Leukemia

Novel agents with different molecular targets continue to emerge for B-cell malignancies, providing fertile ground to study combinations with potentially complementary mechanisms of action. This phase 1 trial evaluates the efficacy and safety of the triplet combination of the novel anti-CD20 agent ublituximab in combination with the PI3Kδ inhibitor TGR-1202 and the Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib in patients with B-cell malignancies.

Eligible patients had chronic lymphocytic leukemia (CLL) or relapsed/refractory non-Hodgkin lymphoma (NHL). There was no limit to prior therapies, including those refractory to prior PI3Kδ or BTK inhibitors. A total of 38 patients were enrolled, of whom 29 were female. The median age was 65 years, and the median number of prior treatments was 3 (range, 0-6). Of the patients, 20 were diagnosed with CLL or small lymphocytic lymphoma (SLL); 18 patients were diagnosed with NHL, consisting of 6 with follicular lymphoma (FL), 6 with diffuse large B-cell lymphoma (DLBCL), 4 with mantle-cell lymphoma (MCL), and 2 with marginal zone lymphoma (MZL).

The maximum tolerated dose was not reached. The combination showed overall response rates of 100% for CLL/SLL (N = 19), MZL (N = 2), and MCL (N = 4); 80% for FL (N = 5); and 17% for DLBCL (N = 6). There was a median follow-up of 11.1 months (0.4-30+ months).

In terms of tolerability, the most common adverse events were diarrhea and fatigue (47% each), dizziness (37%), and insomnia and nausea (34% each). There were relatively few grade 3/4 adverse events; the only event >10% was neutropenia (18%).

The researchers concluded that the combination of ublituximab, TGR-1202, and ibrutinib was well-tolerated, with clinical activity observed across heavily pretreated and high-risk B-cell subgroups. Correlative studies are planned to further understand the potential synergy in different subgroups.

Nastoupil LJ, et al. ASCO Abstract 7511.

Related Items
iFCG for Previously Untreated Patients with CLL with Mutated IGHV and Non-Del(17p)
Conference Correspondent published on June 9, 2017 in ASCO 2017 - Chronic Lymphocytic Leukemia
Results of a Phase 2 Multicenter Study of Obinutuzumab plus Bendamustine in Patients with Previously Untreated CLL
Conference Correspondent published on June 9, 2017 in ASCO 2017 - Chronic Lymphocytic Leukemia
Phase 1 Dose Escalation of Ibrutinib and Buparlisib in Relapsed/Refractory Diffuse Large B-Cell Lymphoma, Mantle-Cell Lymphoma, and Follicular Lymphoma
Conference Correspondent published on June 9, 2017 in ASCO 2017 - Chronic Lymphocytic Leukemia
KI Intolerance Study: A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with CLL Intolerant to Prior Bruton’s Tyrosine Kinase or PI3Kδ Inhibitor Therapy
Conference Correspondent published on June 9, 2017 in ASCO 2017 - Chronic Lymphocytic Leukemia
A Phase 1a/1b Study of a Novel BTK Inhibitor and Combination Products with Everolimus and Pomalidomide in Patients with CLL or Other B-Cell Lymphomas
Conference Correspondent published on June 8, 2017 in ASCO 2017 - Chronic Lymphocytic Leukemia
Last modified: June 7, 2017
  •  Association for Value-Based Cancer Care
  • Oncology Practice Management
  • Value-Based Cancer Care
  • Value-Based Care in Rheumatology
  • Rheumatology Practice Management
  • Urology Practice Management
  • Lynx CME